INDP: Indaptus Therapeutics Inc Company Value to Net Income
Indaptus Therapeutics (INDP) focuses on developing universal cancer treatment methods, targeting oncology centers and research institutes within the massive biotechnology sector. The company is currently conducting primary tests of its molecules, limiting its scope to research alliances. The asset's market dynamics reflect an individual P/E ratio of -24.90. Business success relies on the efficiency of bacterial vectors, patent purity, and access to R&D investment.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwbxec28.yq-7cu2wow&start=20220704&end=20261111&filename=GURU_Markets_-_INDP_-_Indaptus-Therapeutics_-_PE-Multiple "INDP: Indaptus Therapeutics Business Payback Period 07/04/2022 - 11/11/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for Indaptus (INDP)
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
Total Debt to Equity Ratio Indaptus Therapeutics|INDP - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Indaptus Corp|INDP - Company Debts|Debt to Book Value Ratio Indaptus Therapeutics, Inc.|INDP - Company Long-Term Debts|Short-Term Debt Indaptus Therapeutics|Interim Coverage Ratio indaptusrx.com
- earnings and market multiples details:
INDP - Company Net Income|Net Profit Forecast Indaptus Therapeutics|INDP - P/E Multiple|Price to Future Earnings Ratio Indaptus Therapeutics Inc|INDP - PEG Multiple|EV/EBITDA Multiple Indaptus Therapeutics, Inc.|INDP - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Indaptus Therapeutics|INDP - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months indaptusrx.com|INDP - Net earnings per share growth this year|Earnings growth forecast for next year Indaptus Therapeutics
Comprehensive company analysis:indaptusrx.com INDP
When constructing a long-term portfolio, fundamental screening requires a critical analysis of investment payback periods. The price-to-earnings ratio determines the business payback period by measuring the premium for future growth. For Indaptus Therapeutics (INDP), this metric loses its classical meaning due to the lack of revenue prior to FDA approval. By analyzing the company's market P/E level, an investor assesses only the speculative value of the biotech assets.
Key competitors
P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple ADMA (ADMA Bio)|Business Payback Period Protagonist Corp (PTGX)|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|Grifols (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotech|Price to Earnings Ratio CLDX|P/E Multiple Aurinia Corp|Price to Earnings Ratio BioCryst (BCRX)|veratx.com - Price to Earnings Multiple|P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Market Cap to Earnings|AbCellera Bio - P/E Multiple|Business Payback Period Tourmaline TRML|Precigen, Inc. (PGEN) - Price to Earnings Ratio|Price to Earnings Multiple PHAR|NKTR (Nektar Therapeutics Inc.) - P/E Multiple|Price to Earnings Multiple UPB (Upstream Bio, Inc.)|P/E Multiple ZBIO|P/E Multiple Immunome Bio (IMNM)|Price to Earnings Ratio Gossamer Bio, Inc. GOSS|KALV (kalvista.com) - Market Cap to Net Income|SEPN: Price to Earnings Ratio|Pieris Pharma - Market Price to Net Income Ratio|SVRA (Savara Corp) - Price to Earnings Ratio|Rigel Corp (RIGL) - P/E Multiple|Price to Earnings Ratio AnaptysBio, Inc.|astriatx.com (ATXS) - Business Payback Period|Price to Earnings Ratio ENGN (enGene)|RAPT (RAPT Therapeutics Inc.) - Company Value to Net Income|Aerovate Therapeutics - Price to Earnings Ratio|Market Price to Net Income Ratio ACRS (Aclaris Therapeutics, Inc)|Kyverna Therapeutics - P/E Multiple|Company Value to Net Income TLSA (tizianalifesciences.com)|CABA: P/E Multiple|Market Cap to Earnings Ventyx Biosciences Inc. (VTYX)|Price to Earnings Ratio Theratechnologies Inc|AVTX: Company Value to Net Income|P/E Multiple ELDN|P/E Multiple agenusbio.com (AGEN)|Price to Earnings Ratio Climb Bio CLYM|ZURA (Zura Bio Ltd) - Market Cap to Net Income|aTyr - P/E Multiple|Market Cap to Earnings Adagene|IMA (ikenaoncology.com) - Price to Earnings Ratio|Shattuck Labs (STTK) - P/E Multiple|Price to Earnings Ratio EQ|CNTB (Connect Pharma) - Market Price to Net Income Ratio|P/E Multiple IMUX|Business Payback Period atarabio.com|P/E Multiple IFRX (InflaRx)|XFOR - Price to Earnings Ratio|ACET - Price to Earnings Ratio|Business Payback Period Celularity Inc. CELU|INMB: P/E Multiple|BRNS - Business Payback Period|Price to Earnings Ratio Kezar Life Sciences|Price to Earnings Multiple SABS (sabbiotherapeutics.com)|P/E Multiple AKTX|enlivex.com - Price to Earnings Multiple|Price to Earnings Ratio Q32 Bio QTTB|GOVX (GeoVax Corp) - Market Cap to Net Income|EDSA - Price to Earnings Ratio|Market Cap to Net Income IBIO|CARM: P/E Multiple|XTL Biopharmaceuticals Ltd - Company Value to Net Income|BOLT (Bolt Biotherapeutics Inc.) - P/E Multiple|P/E Multiple HCW Biologics Inc|Price to Earnings Ratio Aptevo Therapeutics (APVO)|AIM (AIM ImmunoTech, Inc.) - Company Value to Net Income|Price to Earnings Ratio Aditxt, Inc. ADTX|GRI - Price to Earnings Ratio|XORTX - P/E Multiple|HIND - P/E Multiple|REVB (Revelation Biosciences) - Price to Earnings Ratio|scinai.com - Company Value to Net Income|CALI (CalciMedica Inc) - P/E Multiple|Affimed Therapeutics (AFMD) - Business Payback Period|Price to Earnings Ratio Allakos Inc. (ALLK)|Price to Earnings Ratio hookipapharma.com HOOK|Price to Earnings Ratio IGM Biosciences IGMS|ITOS - Price to Earnings Ratio|OCEA: Price to Earnings Ratio|TCBP - P/E Multiple|Third Harmonic Bio, Inc (THRD) - Price to Earnings Ratio
